StockNews.com initiated coverage on shares of Pulmatrix (NASDAQ:PULM – Free Report) in a report issued on Sunday morning. The firm issued a hold rating on the biotechnology company’s stock.
Pulmatrix Stock Performance
Pulmatrix stock opened at $1.89 on Friday. Pulmatrix has a 52-week low of $1.55 and a 52-week high of $2.88. The firm has a 50 day moving average price of $1.88 and a two-hundred day moving average price of $1.88. The firm has a market cap of $6.89 million, a price-to-earnings ratio of -0.78 and a beta of 0.90.
Pulmatrix (NASDAQ:PULM – Get Free Report) last released its quarterly earnings results on Thursday, March 28th. The biotechnology company reported ($0.57) earnings per share (EPS) for the quarter. Pulmatrix had a negative return on equity of 44.05% and a negative net margin of 75.73%. The firm had revenue of $2.20 million for the quarter.
Pulmatrix Company Profile
Pulmatrix, Inc, a clinical stage biotechnology company, discovers and develops inhaled therapies to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company focuses on developing products based on its inhaled small particles easily respirable and emitted (iSPERSE) technology, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications.
Featured Articles
- Five stocks we like better than Pulmatrix
- 3 Must-Buy Warren Buffett Stocks for Volatile Times
- MarketBeat Week in Review – 5/20 – 5/24
- What is a Dividend Harvesting Strategy and How Can Investors Profit from it?
- NASDAQ 100 vs. NASDAQ Composite: A Detailed Breakdown of NASDAQ
- What to Know About Investing in Penny Stocks
- These 2 Retail Traders Favorites are Nearing Major Breakouts
Receive News & Ratings for Pulmatrix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulmatrix and related companies with MarketBeat.com's FREE daily email newsletter.
